Table 1.

Demographics and baseline characteristics—CX-2029 monotherapy (dose escalation parts A and B) safety analysis population.

Dose CX-2029 (mg/kg)
0.10.250.512345All cohorts
(N = 3)(N = 3)(N = 6)(N = 3)(N = 8)(N = 12)(N = 6)(N = 4)(N = 45)
Median age at enrollment, years (min, max)45 (31, 72)52 (44, 53)59 (38, 67)48 (47, 49)67 (45, 74)66 (52, 75)67 (44, 75)64 (53, 73)60 (31, 75)
Sex, n (%)
 Male01 (33%)5 (83%)3 (100%)5 (63%)9 (75%)4 (67%)1 (25%)28 (62%)
 Female3 (100%)2 (67%)1 (17%)03 (38%)3 (25%)2 (33%)3 (75%)17 (38%)
Race, n (%)
  Asian00001 (13%)1 (8%)002 (4%)
  Black or African American002 (33%)01 (13%)0003 (7%)
  White3 (100%)3 (100%)4 (67%)3 (100%)6 (75%)9 (75%)6 (100%)4 (100%)38 (84%)
  Unknown000002 (17%)002 (4%)
Number of prior cancer treatment regimens, median (min, max)3 (3, 5)4 (1, 8)6 (2, 7)4 (1, 7)4 (1, 5)3 (1, 7)4 (2, 6)3 (3, 16)3 (1, 16)
Median time since last prior cancer treatment end, weeks (min, max)6 (5, 17)4 (3, 126)6 (3, 16)6 (4, 49)9 (4, 53)7 (5, 52)10 (3, 81)8 (5, 10)7 (3, 126)
Cancer type, n (%)
  Adenoid cystic carcinoma of parotid gland001 (17%)0001 (17%)02 (4%)
  Colorectal cancer1 (33%)2 (67%)01 (33%)002 (33%)1 (25%)7 (16%)
  Cutaneous melanoma000001 (8%)001 (2%)
  Endometrial cancer00000001 (25%)1 (2%)
  Head and neck squamous cell cancer00003 (38%)5 (42%)008 (18%)
  Hepatocellular carcinoma00001 (13%)0001 (2%)
  Mesothelioma0000001 (17%)01 (2%)
  NSCLC1 (33%)001 (33%)3 (38%)3 (25%)01 (25%)9 (20%)
  Adenocarcinomaa100031005
  Squamousa000102014
  Ocular melanoma001 (17%)000001 (2%)
  Oncocytic carcinoma of parotid gland001 (17%)000001 (2%)
  Ovarian cancer1 (33%)0000001 (25%)2 (4%)
  Pancreatic cancer000001 (8.3%)001 (2%)
  Perivascular epithelioid cell tumor00001 (13%)0001 (2%)
  Prostate cancer001 (17%)001 (8.3%)1 (17%)03 (7%)
  Soft-tissue sarcoma01 (33%)2 (33%)001 (8.3%)004 (9%)
  Thymoma or thymic cancers0001 (33%)00001 (2%)
  Thyroid carcinoma0000001 (17%)01 (2%)
CD71 (overall) status at baseline, n (%)
  High3 (100%)2 (67%)1 (17%)1 (33%)2 (25%)5 (42%)2 (33%)1 (25%)17 (38%)
  Low005 (83%)2 (67%)5 (63%)3 (25%)3 (50%)3 (75%)21 (47%)
  Unknown01 (33%)001 (13%)4 (33%)1 (17%)07 (16%)
  • Note: Percentages are based on the Safety Analysis Population.

  • aLung cancer histology was not initially captured in the database but was verified as part of a post hoc analysis.